Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
Clinical trial NCT04422392 · TERMINATED
Trial details
- NCT number
- NCT04422392
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-13
- Primary completion
- 2022-09-30
- Enrollment
- 93
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.